【摘要】 已知血源乙型肝炎疫苗（简称血源疫苗）能有效地阻断乙型肝炎传播，个体接种后的免疫效果可持续至少３年。我们对血清ＨＢｅＡｇ阳性和ＨＢｓＡｇ携带者母亲分娩的１０６名新生儿随机分为二组，分别接受美国提供的由酵母菌提取的重组乙型肝炎基因疫苗（简称重组疫苗）和国产血源疫苗，以等剂量和同样的免疫顺序，作对照试验，分析二者对阻断母婴传播的长期效果。以保护性抗体的滴度≥１０ｍＩＵ／ｍｌ的持续存在分析保护效果，指出重组疫苗使用安全无明显副反应；近期的保护效果与血源疫苗相似，而远期效果比血源疫苗长。更多还原

【Abstract】 ne hundred and six neonates born to HBeAg-Positive and HBsAg-Carrier motherswere randomly divided into two groups,In one group each infant received 20 μg perdose of yeast derived recombinant hepatitis B vaccine (recombinant vaccine)and eachinfant in the other group received 20 μg per dose of plasma derived hepatitis B vac-cine(plasma vaccine)on the day of birth,at 1 month and at 6 Inonths (three times). Physical examination and blood testing were performed for all infants at 6,12,24,36, and 48 months of age. The results showed that the protective efficacy rates at 6,12,24,36,and 48 monthswere 66.7%,75.0% , 62.5%, 61.7% and 56.5% respectively for the recombinantvaccine group,and 57.7%, 75.5%, 51.1%, 40.5% and 23.8% respectively for plasmavaccine group.The differences of protective efficacy rates between the two groups werenot statistically significant by Chi-square test in the first two years,and were muchmore significant in the last two years. The study indicates that for the prevention of mother-infant transmission of hepa- titis B virus the protective efficacy of the recombinant vaccine and of the plasma va-ccine are approximate in the near future, and the long term efficacy of the recombinantvaccine is longer than that of the plasma vaccine.更多还原